Met-Related Receptor Tyrosine Kinase Ron in Tumor Growth and Metastasis

Advances in Cancer Research

Volumn 100, Issue , 2008, Pages 1-33

  Wagh, Purnima K ^a,c   Peace, Belinda E ^a,c   Waltz, Susan E ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELDANAMYCIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ID 1; MONOCLONAL ANTIBODY ID 2; PROTEIN TYROSINE KINASE; RECEPTOR BLOCKING AGENT; RON RECEPTOR; SCATTER FACTOR; SMALL INTERFERING RNA; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

BLADDER CANCER; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; CHROMOSOMAL LOCALIZATION; COLON CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; EPITHELIUM CELL; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENE SILENCING; HUMAN; INFLAMMATION; KIDNEY TUMOR; LIGAND BINDING; LIVER CANCER; LIVER CELL; LUNG CANCER; MACROPHAGE; METASTASIS; NONHUMAN; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME MAPPING; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH AND DEVELOPMENT; HEPATOCYTE GROWTH FACTOR; HUMANS; INFLAMMATION; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 46749115181     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(08)00001-8     Document Type: Review

References (117)

1. Angeloni D., Danilkovitch-Miagkova A., Miagkov A., Leonard E.J., and Lerman M.I. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J. Biol. Chem. 279 (2004) 3726-3732
2. Bardella C., Costa B., Maggiora P., Patane S., Olivero M., Ranzani G.N., et al. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 64 (2004) 5154-5161
3. Barlesi F., Tchouhadjian C., Doddoli C., Villani P., Greillier L., Kleisbauer J.P., et al. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: A review of clinical trials from a daily practice perspective. Fundam. Clin. Pharmacol. 19 (2005) 385-393
4. Bezerra J.A., Carrick T.L., Degen J.L., Witte D., and Degen S.J. Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice. J. Clin. Invest. 101 (1998) 1175-1183
5. Bhatt A.S., Takeuchi T., Ylstra B., Ginzinger D., Albertson D., Shuman M.A., et al. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem. 384 (2003) 257-266
6. Bhatt A.S., Welm A., Farady C.J., Vasquez M., Wilson K., and Craik C.S. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc. Natl. Acad. Sci. USA 104 (2007) 5771-5776
7. Brunelleschi S., Penengo L., Lavagno L., Santoro C., Colangelo D., Viano I., et al. Macrophage stimulating protein (MSP) evokes superoxide anion production by human macrophages of different origin. Br. J. Pharmacol. 134 (2001) 1285-1295
8. Camp E.R., Yang A., Gray M.J., Fan F., Hamilton S.R., Evans D.B., et al. Tyrosine kinase receptor RON in human pancreatic cancer: Expression, function, and validation as a target. Cancer 109 (2007) 1030-1039
9. Caponigro F., Formato R., Caraglia M., Normanno N., and Iaffaioli R.V. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr. Opin. Oncol. 17 (2005) 212-217
10. Chan E.L., Peace B.E., Collins M.H., Toney-Earley K., and Waltz S.E. Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 24 (2005) 479-488
11. Chen Q., Seol D.W., Carr B., and Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 26 (1997) 59-66
12. Chen Y.Q., Fisher J.H., and Wang M.H. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: Phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J. Immunol. 161 (1998) 4950-4959
13. Chen Y.Q., Zhou Y.Q., Fu L.H., Wang D., and Wang M.H. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. Carcinogenesis 23 (2002) 1811-1819
14. Cheng H.L., Liu H.S., Lin Y.J., Chen H.H., Hsu P.Y., Chang T.Y., et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br. J. Cancer 92 (2005) 1906-1914
15. Chodosh L.A., Gardner H.P., Rajan J.V., Stairs D.B., Marquis S.T., and Leder P.A. Protein kinase expression during murine mammary development. Dev. Biol. 219 (2000) 259-276
16. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
17. Collesi C., Santoro M.M., Gaudino G., and Comoglio P.M. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol. Cell Biol. 16 (1996) 5518-5526
18. Conrotto P., Corso S., Gamberini S., Comoglio P.M., and Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23 (2004) 5131-5137
19. Correll P.H., Iwama A., Tondat S., Mayrhofer G., Suda T., and Bernstein A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct. 1 (1997) 69-83
20. Cottage A., Clark M., Hawker K., Umrania Y., Wheller D., Bishop M., et al. Three receptor genes for plasminogen related growth factors in the genome of the puffer fish Fugu rubripes. FEBS Lett. 443 (1999) 370-374
21. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr. Cancer Drug Targets 3 (2003) 31-40
22. Danilkovitch-Miagkova A., Angeloni D., Skeel A., Donley S., Lerman M., and Leonard E.J. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J. Biol. Chem. 275 (2000) 14783-14786
23. Danilkovitch-Miagkova A., Miagkov A., Skeel A., Nakaigawa N., Zbar B., and Leonard E.J. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol. Cell. Biol. 21 (2001) 5857-5868
24. Danilkovitch A., Donley S., Skeel A., and Leonard E.J. Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol. Cell. Biol. 20 (2000) 2218-2227
25. Danilkovitch A., Miller M., and Leonard E.J. Interaction of macrophage-stimulating protein with its receptor. Residues critical for beta chain binding and evidence for independent alpha chain binding. J. Biol. Chem. 274 (1999) 29937-29943
26. Danilkovitch A., Skeel A., and Leonard E.J. Macrophage stimulating protein-induced epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent mechanism. Exp. Cell Res. 248 (1999) 575-582
27. De Maria R., Maggiora P., Biolatti B., Prat M., Comoglio P.M., Castagnaro M., et al. Feline STK gene expression in mammary carcinomas. Oncogene 21 (2002) 1785-1790
28. Degen S.J., Stuart L.A., Han S., and Jamison C.S. Characterization of the mouse cDNA and gene coding for a hepatocyte growth factor-like protein: Expression during development. Biochemistry 30 (1991) 9781-9791
29. Federico A., Morgillo F., Tuccillo C., Ciardiello F., and Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 121 (2007) 2381-2386
30. Follenzi A., Bakovic S., Gual P., Stella M.C., Longati P., and Comoglio P.M. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19 (2000) 3041-3049
31. Gaudino G., Avantaggiato V., Follenzi A., Acampora D., Simeone A., and Comoglio P.M. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene 11 (1995) 2627-2637
32. Gaudino G., Follenzi A., Naldini L., Collesi C., Santoro M., Gallo K.A., et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. Embo J. 13 (1994) 3524-3532
33. Germano S., Barberis D., Santoro M.M., Penengo L., Citri A., Yarden Y., et al. Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. J. Biol. Chem. 281 (2006) 21710-21719
34. Ghigna C., Giordano S., Shen H., Benvenuto F., Castiglioni F., Comoglio P.M., et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell 20 (2005) 881-890
35. Han S., Stuart L.A., and Degen S.J. Characterization of the DNF15S2 locus on human chromosome 3: Identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry 30 (1991) 9768-9780
36. Hess K.A., Waltz S.E., Chan E.L., and Degen S.J. Receptor tyrosine kinase Ron is expressed in mouse reproductive tissues during embryo implantation and is important in trophoblast cell function. Biol. Reprod. 68 (2003) 1267-1275
37. Hess K.A., Waltz S.E., Toney-Earley K., and Degen S.J. The receptor tyrosine kinase Ron is expressed in the mouse ovary and regulates inducible nitric oxide synthase levels and ovulation. Fertil. Steril. 80 Suppl 2 (2003) 747-754
38. Hsu P.Y., Liu H.S., Cheng H.L., Tzai T.S., Guo H.R., Ho C.L., et al. Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J. Urol. 176 (2006) 2262-2267
39. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64 (2004) 5355-5362
40. Huff J.L., Jelinek M.A., Borgman C.A., Lansing T.J., and Parsons J.T. The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc. Natl. Acad. Sci. USA 90 (1993) 6140-6144
41. Huff J.L., Jelinek M.A., Jamieson T.A., and Parsons J.T. Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases. Oncogene 12 (1996) 299-307
42. Hurlimann J., and van Melle G. Prognostic value of serum proteins synthesized by breast carcinoma cells. Am. J. Clin. Pathol. 95 (1991) 835-843
43. Hussain S.P., Trivers G.E., Hofseth L.J., He P., Shaikh I., Mechanic L.E., et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res. 64 (2004) 6849-6853
44. Hutchinson J., Jin J., Cardiff R.D., Woodgett J.R., and Muller W.J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell. Biol. 21 (2001) 2203-2212
45. Iwama A., Okano K., Sudo T., Matsuda Y., and Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood 83 (1994) 3160-3169
46. Iwama A., Yamaguchi N., and Suda T. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. Embo J. 15 (1996) 5866-5875
47. Izzedine H., Buhaescu I., Rixe O., and Deray G. Sunitinib malate. Cancer Chemother. Pharmacol. 60 (2007) 357-364
48. Kang J.Y., Dolled-Filhart M., Ocal I.T., Singh B., Lin C.Y., Dickson R.B., et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63 (2003) 1101-1105
49. Kesisis G., Broxterman H., and Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr. Pharm. Des. 13 (2007) 2795-2809
50. Lapraz F., Rottinger E., Duboc V., Range R., Duloquin L., Walton K., et al. RTK and TGF-beta signaling pathways genes in the sea urchin genome. Dev. Biol. 300 (2006) 132-152
51. Lee W.Y., Chen H.H., Chow N.H., Su W.C., Lin P.W., and Guo H.R. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin. Cancer Res. 11 (2005) 2222-2228
52. Leonis M.A., Toney-Earley K., Degen S.J., and Waltz S.E. Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology 36 (2002) 1053-1060
53. Li B.Q., Wang M.H., Kung H.F., Ronsin C., Breathnach R., Leonard E.J., et al. Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor. Biochem. Biophys. Res. Commun. 216 (1995) 110-118
54. Lutz M.A., and Correll P.H. Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C zeta. J Leukoc. Biol. 73 (2003) 802-814
55. Maggiora P., Lorenzato A., Fracchioli S., Costa B., Castagnaro M., Arisio R., et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell Res. 288 (2003) 382-389
56. Maggiora P., Marchio S., Stella M.C., Giai M., Belfiore A., De Bortoli M., et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 16 (1998) 2927-2933
57. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
58. Maroun C.R., Naujokas M.A., Holgado-Madruga M., Wong A.J., and Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 20 (2000) 8513-8525
59. Massot O., Baskevitch P.P., Capony F., Garcia M., and Rochefort H. Estradiol increases the production of alpha 1-antichymotrypsin in MCF7 and T47D human breast cancer cell lines. Mol. Cell Endocrinol. 42 (1985) 207-214
60. Medico E., Mongiovi A.M., Huff J., Jelinek M.A., Follenzi A., Gaudino G., et al. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol. Biol. Cell 7 (1996) 495-504
61. Mera A., Suga M., Ando M., Suda T., and Yamaguchi N. Induction of cell shape changes through activation of the interleukin-3 common beta chain receptor by the RON receptor-type tyrosine kinase. J. Biol. Chem. 274 (1999) 15766-15774
62. Montero-Julian F.A., Dauny I., Flavetta S., Ronsin C., Andre F., Xerri L., et al. Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor. Hybridoma 17 (1998) 541-551
63. Muraoka R.S., Sun W.Y., Colbert M.C., Waltz S.E., Witte D.P., Degen J.L., et al. The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J. Clin. Invest. 103 (1999) 1277-1285
64. Nishigaki K., Thompson D., Hanson C., Yugawa T., and Ruscetti S. The envelope glycoprotein of friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase Stk. J. Virol. 75 (2001) 7893-7903
65. O'Toole J.M., Rabenau K.E., Burns K., Lu D., Mangalampalli V., Balderes P., et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res. 66 (2006) 9162-9170
66. Okino T., Egami H., Ohmachi H., Takai E., Tamori Y., Nakagawa K., et al. Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. Int. J. Oncol. 15 (1999) 709-714
67. Okino T., Onda M., Matsukura N., Inada K.I., Tatematsu M., Suzuki S., et al. Sequential histopathological changes in vivo after suicide gene therapy of gastric cancer induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. Jpn. J. Cancer Res. 92 (2001) 673-679
68. Peace B.E., Hill K.J., Degen S.J., and Waltz S.E. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp. Cell. Res. 289 (2003) 317-325
69. Peace B.E., Hughes M.J., Degen S.J., and Waltz S.E. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 20 (2001) 6142-6151
70. Peace B.E., Toney-Earley K., Collins M.H., and Waltz S.E. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res. 65 (2005) 1285-1293
71. Persons D.A., Paulson R.F., Loyd M.R., Herley M.T., Bodner S.M., Bernstein A., et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat. Genet. 23 (1999) 159-165
72. Perwez Hussain S., and Harris C.C. Inflammation and cancer: An ancient link with novel potentials. Int. J. Cancer 121 (2007) 2373-2380
73. Plosker G.L., and Keam S.J. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66 (2006) 449-475
74. Quantin B., Schuhbaur B., Gesnel M.C., Doll'e P., and Breathnach R. Restricted expression of the ron gene encoding the macrophage stimulating protein receptor during mouse development. Dev. Dyn. 204 (1995) 383-390
75. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64 (2004) 3958-3965
76. Rampino T., Collesi C., Gregorini M., Maggio M., Soccio G., Guallini P., et al. Macrophage-stimulating protein is produced by tubular cells and activates mesangial cells. J. Am. Soc. Nephrol. 13 (2002) 649-657
77. Rampino T., Gregorini M., Soccio G., Maggio M., Rosso R., Malvezzi P., et al. The Ron proto-oncogene product is a phenotypic marker of renal oncocytoma. Am. J. Surg. Pathol. 27 (2003) 779-785
78. Ronsin C., Muscatelli F., Mattei M.G., and Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8 (1993) 1195-1202
79. Roque R.S., Caldwell R.B., and Behzadian M.A. Cultured Muller cells have high levels of epidermal growth factor receptors. Invest. Ophthalmol. Vis. Sci. 33 (1992) 2587-2595
80. Sacco M.G., Soldati S., Indraccolo S., Cato E.M., Cattaneo L., Scanziani E., et al. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther. 10 (2003) 1903-1909
81. Sakamoto O., Iwama A., Amitani R., Takehara T., Yamaguchi N., Yamamoto T., et al. Role of macrophage-stimulating protein and its receptor, RON tyrosine kinase, in ciliary motility. J. Clin. Invest. 99 (1997) 701-709
82. Santoro M.M., Collesi C., Grisendi S., Gaudino G., and Comoglio P.M. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol. Cell. Biol. 16 (1996) 7072-7083
83. Santoro M.M., Gaudino G., and Marchisio P.C. The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev. Cell 5 (2003) 257-271
84. Santoro M.M., Penengo L., Minetto M., Orecchia S., Cilli M., and Gaudino G. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 17 (1998) 741-749
85. Senchenko V., Liu J., Braga E., Mazurenko N., Loginov W., Seryogin Y., et al. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene 22 (2003) 2984-2992
86. Senchenko V.N., Liu J., Loginov W., Bazov I., Angeloni D., Seryogin Y., et al. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23 (2004) 5719-5728
87. Shimamoto A., Kimura T., Matsumoto K., and Nakamura T. Hepatocyte growth factor-like protein is identical to macrophage stimulating protein. FEBS Lett. 333 (1993) 61-66
88. Skeel A., and Leonard E.J. Action and target cell specificity of human macrophage-stimulating protein (MSP). J. Immunol. 152 (1994) 4618-4623
89. Skeel A., and Leonard E.J. Alpha 1-antichymotrypsin is the human plasma inhibitor of macrophage ectoenzymes that cleave pro-macrophage stimulating protein. J. Biol. Chem. 276 (2001) 21932-21937
90. Skeel A., Yoshimura T., Showalter S.D., Tanaka S., Appella E., and Leonard E.J. Macrophage stimulating protein: Purification, partial amino acid sequence, and cellular activity. J. Exp. Med. 173 (1991) 1227-1234
91. Thomas R.M., Toney K., Fenoglio-Preiser C., Revelo-Penafiel M.P., Hingorani S.R., Tuveson D.A., et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 67 (2007) 6075-6082
92. van den Akker E., van Dijk T., Parren-van Amelsvoort M., Grossmann K.S., Schaeper U., Toney-Earley K., et al. Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood 103 (2004) 4457-4465
93. Wahl R.C., Hsu R.Y., Huff J.L., Jelinek M.A., Chen K., Courchesne P., et al. Chicken macrophage stimulating protein is a ligand of the receptor protein-tyrosine kinase Sea. J. Biol. Chem. 274 (1999) 26361-26368
94. Waltz S.E., Eaton L., Toney-Earley K., Hess K.A., Peace B.E., Ihlendorf J.R., et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J. Clin. Invest. 108 (2001) 567-576
95. Waltz S.E., Gould F.K., Air E.L., McDowell S.A., and Degen S.J. Hepatocyte nuclear factor-4 is responsible for the liver-specific expression of the gene coding for hepatocyte growth factor-like protein. J. Biol. Chem. 271 (1996) 9024-9032
96. Waltz S.E., McDowell S.A., Muraoka R.S., Air E.L., Flick L.M., Chen Y.Q., et al. Functional characterization of domains contained in hepatocyte growth factor-like protein. J. Biol. Chem. 272 (1997) 30526-30537
97. Waltz S.E., Toms C.L., McDowell S.A., Clay L.A., Muraoka R.S., Air E.L., et al. Characterization of the mouse Ron/Stk receptor tyrosine kinase gene. Oncogene 16 (1998) 27-42
98. Wang D., Shen Q., Chen Y.Q., and Wang M.H. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: Roles of the RON receptor tyrosine kinase. Oncogene 23 (2004) 1668-1680
99. Wang M.H., Cox G.W., Yoshimura T., Sheffler L.A., Skeel A., and Leonard E.J. Macrophage-stimulating protein inhibits induction of nitric oxide production by endotoxin- or cytokine-stimulated mouse macrophages. J. Biol. Chem. 269 (1994) 14027-14031
100. Wang M.H., Dlugosz A.A., Sun Y., Suda T., Skeel A., and Leonard E.J. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp. Cell. Res. 226 (1996) 39-46
101. Wang M.H., Kurtz A.L., and Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21 (2000) 1507-1512
102. Wang M.H., Montero-Julian F.A., Dauny I., and Leonard E.J. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 13 (1996) 2167-2175
103. Wang M.H., Ronsin C., Gesnel M.C., Coupey L., Skeel A., Leonard E.J., et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 266 (1994) 117-119
104. Wang M.H., Skeel A., and Leonard E.J. Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases. J. Clin. Invest. 97 (1996) 720-727
105. Wang M.H., Yoshimura T., Skeel A., and Leonard E.J. Proteolytic conversion of single chain precursor macrophage-stimulating protein to a biologically active heterodimer by contact enzymes of the coagulation cascade. J. Biol. Chem. 269 (1994) 3436-3440
106. Wei X., Hao L., Ni S., Liu Q., Xu J., and Correll P.H. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity. J. Biol. Chem. 280 (2005) 40241-40251
107. Welm A.L., Sneddon J.B., Taylor C., Nuyten D.S., van de Vijver M.J., Hasegawa B.H., et al. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc. Natl. Acad. Sci. USA 104 (2007) 7570-7575
108. Wetzel C.C., Degen S.J., and Waltz S.E. Cis-acting elements in the hepatocyte growth factor-like protein gene regulate kidney and liver-specific expression in mice. DNA Cell Biol. 22 (2003) 293-301
109. Willett C.G., Smith D.I., Shridhar V., Wang M.H., Emanuel R.L., Patidar K., et al. Differential screening of a human chromosome 3 library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in injured lung. Possible implications for neuroendocrine cell survival. J. Clin. Invest. 99 (1997) 2979-2991
110. Willett C.G., Wang M.H., Emanuel R.L., Graham S.A., Smith D.I., Shridhar V., et al. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: Induction of receptor tyrosine phosphorylation and cell migration. Am. J. Respir. Cell Mol. Biol. 18 (1998) 489-496
111. Williams T.A., Longati P., Pugliese L., Gual P., Bardelli A., and Michieli P. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. J. Cell. Physiol. 181 (1999) 507-514
112. Wong T.W., Lee F.Y., Yu C., Luo F.R., Oppenheimer S., Zhang H., et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin. Cancer Res. 12 (2006) 6186-6193
113. Xu X.M., Wang D., Shen Q., Chen Y.Q., and Wang M.H. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23 (2004) 8464-8474
114. Yoshimura T., Yuhki N., Wang M.H., Skeel A., and Leonard E.J. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J. Biol. Chem. 268 (1993) 15461-15468
115. Zalcenstein A., Weisz L., Stambolsky P., Bar J., Rotter V., and Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25 (2006) 359-369
116. Zhou Y.Q., He C., Chen Y.Q., Wang D., and Wang M.H. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: Generation of different splicing RON variants and their oncogenic potential. Oncogene 22 (2003) 186-197
117. Zinser G.M., Leonis M.A., Toney K., Pathrose P., Thobe M., Kader S.A., et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res. 66 (2006) 11967-11974